Project Grant R01CA303125
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $745K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded a $671,252 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Biology Research program (CFDA 93.396) to investigate the mechanisms of anti-tumor immunity mediated by immune cell triads. The research project, effective from July 1, 2026 through June 30, 2031, will advance fundamental understanding of how CD4 T cells, CD8 T cells, and dendritic cells must spatially organize and interact within tumors...
- The National Cancer Institute awarded a $1,542,555 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Treatment Research program (CFDA 93.395). The grant will fund research from December 2022 through November 2027 to develop more effective treatments for localized bladder cancer. Specifically, the grantee will conduct genomic analyses of bladder cancer patient cohorts to validate DNA damage response mutations as predictors of sensitivity to bacillus Calmette-Guérin...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $730,097 to the Sloan-Kettering Institute for Cancer Research, effective May 1, 2026 through April 30, 2031, under the Cancer Treatment Research program (CFDA 93.395). This research project addresses the suppression of anti-tumor T-cell immunity in gastric adenocarcinoma by investigating how chronic inflammation induces KLF-2 (Krüppel-like factor 2)—a quiescence-associated transcription factor—in...
- Federal Project Grant Award Summary Funding Agency: National Cancer Institute Program: Cancer Biology Research (CFDA 93.396) Award Amount: $452,540 Award Period: May 1, 2026 – April 30, 2028 Awardee: Sloan-Kettering Institute for Cancer Research Sloan-Kettering Institute for Cancer Research will conduct fundamental research to elucidate the innate and adaptive immune determinants underlying cytokine release syndrome (CRS) in chimeric antigen receptor (CAR) T cell therapies for hematologic...
- Federal Project Grant Award Summary The National Cancer Institute awarded $1,034,176 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, for a project extending through July 31, 2032. The research focuses on understanding and targeting aberrant RNA splicing in leukemia, building on the principal investigator's 13-year track record of discovering genetic alterations in hematopoietic malignancies. The project aims to...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a $752,808 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 1, 2026, with completion targeted for May 31, 2031. The award funds research investigating clonal hematopoiesis (CH)—the clonal expansion of mutated blood-forming cells in aging individuals—as a mechanism of therapeutic resistance in anaplastic thyroid cancer (ATC). The research...
- Federal Project Grant Award Summary The National Cancer Institute awarded $292,028 to Sloan-Kettering Institute for Cancer Research under the Cancer Research Manpower program (CFDA 93.398) beginning August 1, 2025, and concluding July 31, 2030. This five-year Project Grant supports research investigating genome instability associated with focal oncogene amplification (OA) and the development of therapeutic strategies to address treatment-resistant cancers. The research deliverables include...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a Project Grant totaling $546,842 (awarded July 1, 2026; completion June 30, 2031) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct research on germline determinants of tumor development and treatment response. The project will deliver a meta-analysis framework and functional validation studies identifying how inherited germline...